Carlyle Group Inc.Carlyle Group Inc.

Institutional investor · Portfolio as of Q4 2019

SEC EDGAR SourceSEC Filings

Top Holdings12 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
EVAEVA
Unit

ENVIVA PARTNERS LP

12.7M$475.5M31.5%
5 qtrssince 2018-Q4
Increased
72

LIBERTY ENERGY INC

34.1M$378.7M25.1%$11.90-12.02%
5 qtrssince 2018-Q4
Decreased
0

WESCO AIRCRAFT HOLDINGS INC

23.1M$254.5M16.9%
5 qtrssince 2018-Q4
Unchanged
0
31M$206.9M13.7%
5 qtrssince 2018-Q4
Unchanged
0
172.9M$147.7M9.8%
4 qtrssince 2019-Q1
Unchanged
0

SEACOR MARINE HLDGS INC

1.1M$14.7M1.0%$12.00+14.58%
5 qtrssince 2018-Q4
Unchanged
0
CIHCIHDelisted
ADR

CHINA INDEX HLDGS LTD

2.5M$9M0.6%
3 qtrssince 2019-Q2
Unchanged
0
??FANG HLDGS LTDDelisted
ADR
2.5M$7M0.5%
New
48

RING ENERGY INC

2.6M$6.9M0.5%$1.66+52.41%
2 qtrssince 2019-Q3
Unchanged
0
1.3M$5.9M0.4%
5 qtrssince 2018-Q4
Unchanged
0
6.4M$2.2M0.1%
5 qtrssince 2018-Q4
Unchanged
0

Sweetgreen, Inc.

174,170$1.5M0.1%
5 qtrssince 2018-Q4
Unchanged
0
$1.5B
AUM
12
Positions
Q4 2019
Filing
Rating · 1.5
Quarterly Portfolio Change
Not enough history yet
Activity profile
$ moved · Q4'19
New4%Increased65%Decreased28%Exited3%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.2 quarters
<1Q8%1-4Q25%1-2Y67%2Y+0%

Carlyle Group Inc. manages $1.5B across 12 positions as of Q4 2019. Top holdings: EVA (31.5%), LBRT (25.1%), WAIR (16.9%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.

Q4 2019 Summary

Added 1 new position, exited 1, increased 1, trimmed 1. Top move: EVA (INCREASED, conviction 72). Portfolio: $1.5B across 12 positions.

Top holdings by portfolio weight

Total AUM$2B
EVA31.48%
LBRT25.07%
WAIR16.85%
ONESMART INT13.70%
CS19.78%
SMHI0.97%
CIH0.59%
FANG HLDGS L0.47%
REI0.46%
CDEV0.39%
Other0.14%

Portfolio allocation by GICS sector

Sectors4
Unknown68.96%
Energy29.79%
Industrials1.13%
Consumer Cyclical0.12%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Unknown, Energy
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction38
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used